Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna ( MRNA ).
Looking at options history for Moderna ( MRNA ) we detected 14 trades.
If we consider the specifics of each trade, it is accurate to state that 57% of the investors opened trades with bullish expectations and 35% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $1,135,204 and 7, calls, for a total amount of $483,749.
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $30.0 to $60.0 for Moderna ( MRNA ) over the recent three months.
In today's trading context, the average open interest for options of Moderna ( MRNA ) stands at 3878.9, with a total volume reaching 3,512.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Moderna ( MRNA ), situated within the strike price corridor from $30.0 to $60.0, throughout the last 30 days.
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MRNA | PUT | TRADE | BEARISH | 1.9K | 1.2K | ||||||
| MRNA | PUT | SWEEP | BEARISH | 13.7K | 408 | ||||||
| MRNA | CALL | SWEEP | BULLISH | 4.0K | 569 | ||||||
| MRNA | CALL | SWEEP | BULLISH | 6.6K | 7 | ||||||
| MRNA | PUT | TRADE | BULLISH | 7.4K | 543 |
Moderna ( MRNA ) is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna ( MRNA ) had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Currently trading with a volume of 4,492,595, the MRNA's price is down by -2.28%, now at $30.38.
RSI readings suggest the stock is currently may be approaching oversold.
Anticipated earnings release is in 62 days.
In the last month, 4 experts released ratings on this stock with an average target price of $49.25.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access.
* An analyst from UBS has decided to maintain their Buy rating on Moderna ( MRNA ), which currently sits at a price target of $78.
* Consistent in their evaluation, an analyst from B of A Securities keeps a Underperform rating on Moderna ( MRNA ) with a target price of $34.
* An analyst from RBC Capital downgraded its action to Sector Perform with a price target of $40.
* Reflecting concerns, an analyst from Barclays lowers its rating to Equal-Weight with a new price target of $45.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Moderna ( MRNA ), Benzinga Pro gives you real-time options trades alerts.